Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 27, 2008, Pages 4418-4425

  Barve, Minal ^a   Bender, James ^a   Senzer, Neil ^a   Cunningham, Casey ^a   Greco, F Anthony ^a   McCune, David ^a   Steis, Ronald ^a   Khong, Hung ^a   Richards, Donald ^a   Stephenson, Joe ^a   Ganesa, Prasanthi ^a   Nemunaitis, Jackie ^a   Ishioka, Glenn ^a   Pappen, Beena ^a   Nemunaitis, Michael ^a   Morse, Michael ^a   Mills, Bonnie ^a   Maples, Phillip B ^a   Sherman, Jeffrey ^a   Nemunaitis, John J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELAGENPUMATUCEL; CANCER VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A2 ANTIGEN; IDM 2101; LUCANIX; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HELPER CELL; HEMATOLOGIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 52449108084     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.6462     Document Type: Article

References (61)

1. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
2. Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477-484, 2001
3. Fong L, Hou Y, Rivas A, et al: Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98:8809-8814, 2001
4. Slodkowska J, Szturmowicz M, Rudzinski P, et al: Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels. Eur J Cancer Prev 7:51-60, 1998
5. Fijo?ek J, Wiatr E, Rowinska-Zakrzewska E, et al: p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers 21:81-87, 2006
6. Tsao MS, Aviel-Ronen S, Ding K, et al: Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol 25:5240-5247, 2007
7. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001
8. Vallböhmer D, Brabender J, Yang DY, et al: Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin Lung Cancer 7:332-337, 2006
9. Sienel W, Varwerk C, Linder A, et al: Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: Results of a multi-center study. Eur J Cardiothorac Surg 25:131-134, 2004
10. Marshall JL, Hoyer RJ, Toomey MA, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964-3973, 2000
11. Arlen P, Tsang KY, Marshall JL, et al: The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 49:517-529, 2000
12. Hörig H, Lee DS, Conkright W, et al: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 49:504-514, 2000
13. Vierboom MP, Nijman HW, Offringa R, et al: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695-704, 1997
14. Vierboom MP, Bos GM, Ooms M, et al: Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 87:253-260, 2000
15. Rosenwirth B, Kuhn EM, Heeney JL, et al: Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine 19:1661-1670, 2001
16. van der Burg SH, de Cock K, Menon AG, et al: Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 31:146-155, 2001
17. Ferriè s E, Connan F, Pages F, et al: Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Hum Immunol 62:791-798, 2001
18. Tartaglia J, Bonnet MC, Berinstein N, et al: Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 19(17-19):2571-2575, 2001
19. National Institutes of Health: ClinicalTrials-.gov. http://www. clinicaltrials.gov./
20. van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647, 1991
21. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
22. Weber JS, Hua FL, Spears L, et al: A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 22:431-440, 1999
23. Coulie PG, Karanikas V, Colau D, et al: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 98:10290-10295, 2001
24. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
25. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
26. Disis ML, Calenoff E, McLaughlin G, et al: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20, 1994
27. Alexander J, Sidney J, Southwood S, et al: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1:751-761, 1994
28. Keogh E, Fikes J, Southwood S, et al: Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 167:787-796, 2001
29. Tangri S, Ishioka GY, Huang X, et al: Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194:833-846, 2001
30. Kavanagh B, Ko A, Venook A, et al: Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 30:762-772, 2007
31. Kawashima I, Hudson SJ, Tsai V, et al: The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various trumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59:1-14, 1998
32. Zaremba S, Barzaga E, Zhu M, et al: Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570-4577, 1997
33. Rongcun Y, Salazar-Onfray F, Charo J, et al: Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163:1037-1044, 1999
34. Meyer zum Büschenfel C, Nicklisch N, Rose-John S, et al: Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J Immunol 165:4133-4140, 2000
35. Lustgarten J, Theobald M, Labadie C, et al: Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD. 8. Hum Immunol 52:109-118, 1997
36. Chikamatsu K, Nakano K, Storkus WJ, et al: Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 5:1281-1288, 1999
37. Visseren MJ, van der Burg SH, van der Voort EI, et al: Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 73:125-130, 1997
38. Petersen TR, Buus S, Brunak S, et al: Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 53:357-364, 2001
39. Theobald M, Biggs J, Dittmer D, et al: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 92:11993-11997, 1995
40. Wentworth PA, Vitiello A, Sidney J, et al: Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 26:97-101, 1996
41. Vitiello A, Marchesini D, Furze J, et al: Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 173:1007-1015, 1991
42. Wentworth PA, Sette A, Celis E, et al: Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 8:651-659, 1996
43. McKinney DM, Skvoretz R, Qin M, et al: Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization. J Immunol Methods 237:105-117, 2000
44. Ishioka GY, Disis ML, Morse MA, et al: Multi-epitope CTL responses induced by a peptide vaccine (EP-2101) in colon and non-small cell lung cancer patients. J Immunother 27:S23-S24, 2004 (suppl; abstr)
45. Vonderheide RH, Domchek SM, Schultze JL, et al: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828-839, 2004
46. Yamshchikov GV, Barnd DL, Eastham S, et al: Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 92:703-711, 2001
47. Beebe MB, Qin M, Moi M, et al: Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy. Hum Vaccin 4:210-218, 2007
48. Wang F, Bade E, Kuniyoshi C, et al: Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5:2756-2765, 1999
49. Cormier JN, Salgaller ML, Prevette T, et al: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37-44, 1997
50. Salgaller ML, Marincola FM, Cormier JN, et al: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749-4757, 1996
51. Muderspach L, Wilczynski S, Roman L, et al: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416, 2000
52. Ressing ME, van Driel WJ, Brandt RM, et al: Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255-266, 2000
53. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
54. Socinski MA, Morris DE, Masters GA, et al: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123:226S-243S, 2003 (suppl)
55. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
56. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
57. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246, 2003
58. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
59. Nemunaitis J, Jahan T, Ross H, et al: Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 13:555-562, 2006
60. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al: Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24:4721-4730, 2006
61. Peoples GE, Gurney JM, Hueman MT, et al: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536-7545, 2005